Outcomes of Belimumab Use for Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry

Project Period:

Grant Category:
Data Analysis Support Grant

Disease Area:
Lupus and Related Conditions (SLE/RC)

Belimumab (Benlysta), a B-cell directed biologic medication, is FDA-approved for the treatment of systemic lupus erythematosus in both children and adults. Real-world effectiveness data in adults shows that patients who start belimumab have fewer lupus flares and need lower steroid doses. However, there is little data on how well belimumab works for children and young adults with lupus. In Aim 1, we will describe characteristics of patients who have received belimumab in the CARRA Registry to better understand current use. In Aim 2, we will compare disease activity, patient reported quality of life, and daily steroid doses at belimumab initiation, to 6 and 12 months after. This will be the first large multicenter study of belimumab in a real-world use setting in children and will provide essential data on belimumab effectiveness and safety.


Jordan Roberts, MD

Seattle Children's Hospital

Related Awarded Grants

Disease Area:
Lupus and Related Conditions (SLE/RC)

CARRA Samples for funded LRA Global Team Science Award